Partner With Us NRI

Aarti Drugs Ltd share Price

Company details

6M Return 46.13%
1Y Return 17.02%
Mkt Cap.(Cr) 5,108.74
Volume 14,485
Div Yield 0.18%
OI Chg %
Volume 14,485

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Aarti Drugs announced Q1FY24 results: 

  • Consolidated Q1FY24:
    • Revenue stood at Rs 661.7 crore as against Rs 622.2 crore, a growth of 6% YoY
    • EBITDA stood at Rs 84.7 crore as against Rs 67.4 crore YoY. EBITDA Margin (%) came in at 12.8%
    • PAT stood at Rs 48.0 crore as against Rs 34.8 crore YoY. PAT Margin (%) stood at 7.3%
  • Standalone Q1FY24:
    • Standalone Q1FY24 revenue stood at Rs 591.6 crore as against Rs 551.2 crore, a growth of 7.3% YoY
    • The standalone business contributed ~86% to the consolidated revenue for Q1FY24
    • API volumes grew considerably at ~18%, led by secular growth across acute as well as chronic therapies
    • ~68% of the revenues came from the domestic market and 32% from the exports market for Q1FY24 for a standalone business
    • Domestic revenue grew approximately by 13.6% while exports de-grew by around 4.0% YoY for Q1FY24
    • Within the API business, the antibiotic therapeutic category contributed ~48%, anti-diabetic ~13%, anti-protozoal ~17%, anti-inflammatory ~11%, antifungal ~7% and the rest contributed ~4% to total API sales for Q1FY24
    • Q1FY24 revenue for formulation stood at Rs 89.9 crore as against Rs 85.0 crore. ~67% of the revenue contribution is from exports during Q1FY24

Commenting on the same, Adhish Patil, CFO & COO, Aarti Drugs said, “The company posted revenue growth of ~6.3% YoY in Q1FY24, which was primarily driven by good volume growth getting partially set off by the downward rate variance. Growth in API business was led by volume growth of 18% driven by domestic market demand uplift. The company expects improved margin levels each quarter from now onwards as the input price is seen to be stabilized, which is also witnessed in our Q1FY24 margin performance, though there might be a few products specific instances where raw materials are still showing a downward trend. Moreover, exports have been a laggard for API this quarter due to USD shortages for some of the export geographies.

Formulation segment revenue stood at Rs 90 crore for the quarter, a growth of 6% YoY. The formulation segment contributed ~14% to the consolidated revenue for the quarter. Exports continued to remain a key focus area for the formulation segment. ~67% of the formulation revenue came from exports during the quarter led by new business gains.

The specialty Chemical industry, globally, has been in a tepid environment where demand is seen as weaker which also affected our business in some ways. We have set out action plans to mitigate this impact and expect to grasp every possible opportunity to grow in this area. Specialty Chemical business was impacted YoY, due to the absence of a couple of campaign-based products in the Jun’23 quarter.

The CAPEX for Q1 FY24 stood at ~Rs 48 crore and is expected to be in the range of Rs 250-350 crore for FY24. With all the Capex plans getting executed this fiscal year i.e. Gujarat Saykha Capex, Tarapur Capex on Dermatology and Specialty chemical, which are high margin accretive segments that will gain better growth to our business. Due to some external factors, the project is now expected to come into commercial operations in Q3FY24.

Looking beyond the short-term challenges, we remain positive about the opportunities both in API and non-API business. The growth trajectory is expected to be healthy for all the segments in the upcoming period driven by the execution of existing projects and higher utilization of existing capacities. The pace of growth in exports is expected to continue in the formulation business.”



Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Aarti Drugs Ltd Stocks COMPARISION


Equity Capital: 1,192.43 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 12,500.03 -6,885.48
LAST 3M 36,702.89 2,100.69
LAST 6M 45,999.05 152,168.44
LAST 12M 133,371.71 158,810.39

Aarti Drugs Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Aarti Drugs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 5,768.98 crores, it is incorporated in the year 1984. It features consolidated sales of Rs. 579.95 crores in June 2021. It is also listed in the Bombay Stock Exchange (BSE) with the code 524348 and listed in the National Stock Exchange (NSE) with the code AARTIDRUGS.

    Aarti Drugs Ltd was incorporated as a private limited company on 28th September ’1984 and converted into a public limited company in 1992. It is owned by Aarti Industries Ltd, which also owns a Research & Development plant in Tarapur, Maharashtra. The Company is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private Limited. The Company operates through eight manufacturing facilities, two of which are strategically located in the state of Gujarat and Maharashtra. Also, all the manufacturing units of Aarti Industries are GMP certified, and therefore, the Company is additionally in the process of acquiring certification as per ISO 9002 compliance standard for all its units, out of which one has received the certification. The promoters of the Company currently hold 60.14% of the stake in the Company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 2.57% and 2% of the stake. The balance of 35.29% is held by others (retail investors).

    In June 2021, quarterly net sales were Rs. 505.79 crores, which has increased by approximately 6.36% from Rs. 475.55 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 45.54 crores, which has fallen by 37.64% from a net profit of Rs. 73.03 crores in June 2020. In June 2021, the operating profit was Rs. 429.79 crores, which is also increased by 3.51% as compared to the operating profit of Rs. 415.22 crores for the quarter ending in June 2020. From Rs. 31.34 in June 2020, the EPS of Aarti Drugs has been reduced to just Rs. 4.9 per share in June 2021. AARTIDRUGS’s stock closed at Rs. 634.80 on 16th August’2021 (NSE) and has returned -1.50% in the last six months and -70.23% in the last year.

Registered Address

Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal, Thane, Maharashtra, 401506

Tel : 91-22-24072249
Email : investorrelations:aartidrugs.com
Website : http://www.aartidrugs.com

Sharepro Services

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524348
Book Closure Date (Month) :
BSE Group : A
ISIN : INE767A01016

FAQ’s on Aarti Drugs Ltd Shares

You can buy Aarti Drugs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aarti Drugs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 25, 2023 09:19 AM the closing price of Aarti Drugs Ltd was ₹ 551.70.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 25, 2023 09:19 AM, the market cap of Aarti Drugs Ltd stood at ₹ 5,108.74.

The latest PE ratio of Aarti Drugs Ltd as of Sep 25, 2023 09:19 AM is 28.51

The latest PB ratio of Aarti Drugs Ltd as of Sep 25, 2023 09:19 AM is 0.23

The 52-week high of Aarti Drugs Ltd is ₹ 645.75 while the 52-week low is ₹ 313.90

Download Our App

market app
market app